Abstract
Background
The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed.Methods
Autonomic and clinical features, quantitative cardiovascular autonomic function, and potential autonomic prognostic markers of disease progression were recorded in a cohort of individuals with hereditary transthyretin amyloidosis and in asymptomatic carriers of TTR variants at disease onset (T0) and at the time of the first quantitative autonomic assessment (T1). The severity of peripheral neuropathy and its progression was stratified with the polyneuropathy disability score.Results
A total of 124 individuals were included (111 with a confirmed diagnosis of hereditary transthyretin amyloidosis, and 13 asymptomatic carriers of TTR variants). Symptoms of autonomic dysfunction were reported by 27% individuals at T0. Disease duration was 4.5 ± 4.0 years [mean ± standard deviation (SD)] at autonomic testing (T1). Symptoms of autonomic dysfunction were reported by 78% individuals at T1. Cardiovascular autonomic failure was detected by functional testing in 75% individuals and in 64% of TTR carriers. Progression rate from polyneuropathy disability stages I/II to III/IV seemed to be shorter for individuals with autonomic symptoms at onset [2.33 ± 0.56 versus 4.00 ± 0.69 years (mean ± SD)].Conclusions
Cardiovascular autonomic dysfunction occurs early and frequently in individuals with hereditary transthyretin amyloidosis within 4.5 years from disease onset. Cardiovascular autonomic failure can be subclinical in individuals and asymptomatic carriers, and only detected with autonomic function testing, which should be considered a potential biomarker for early diagnosis and disease progression.Full text links
Read article at publisher's site: https://doi.org/10.1007/s10286-024-01038-z
Read article for free, from open access legal sources, via Unpaywall: https://www.researchsquare.com/article/rs-4003951/latest.pdf
References
Articles referenced by this article (44)
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.
Neurol Ther, (2):317-333 2020
MED: 32948978
Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study.
J Neurol Neurosurg Psychiatry, (1):45-49 1995
MED: 7608709
A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK.
J Neurol Neurosurg Psychiatry, (6):620-627 2015
MED: 26243339
Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment.
Lancet Neurol, (11):1061-1074 2023
MED: 37863593
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.
J Neurol Neurosurg Psychiatry, (6):668-678 2022
MED: 35256455
Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis.
Clin Auton Res, (1):15-22 2023
MED: 36625973
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Amyloid, (4):228-236 2022
MED: 35730447
Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
Neurol Ther, (2):865-886 2021
MED: 34355354
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Amyloid, (1):14-22 2021
MED: 34632904
Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years.
Am J Transplant, (11):2597-2604 2007
MED: 17868062
Show 10 more references (10 of 44)
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Amyloid, 31(2):132-141, 13 Mar 2024
Cited by: 2 articles | PMID: 38477065
Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Ann Med, 53(1):1787-1796, 01 Dec 2021
Cited by: 7 articles | PMID: 34658264 | PMCID: PMC8525987
Hereditary Transthyretin Amyloidosis
University of Washington, Seattle, Seattle (WA), 17 Jun 2021
Cited by: 0 articles | PMID: 20301373
ReviewBooks & documents Free full text in Europe PMC